FDA Publishes All 7 Briefing Documents Ahead of the July 2026 PCAC Meeting

The U.S. Food and Drug Administration has posted all seven briefing documents for the July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting. These documents are the FDA's detailed scientific evaluations of each peptide under review and will heavily influence the committee's recommendations on 503A compounding.

This is a major development. The briefing documents reveal how the agency is currently weighing the safety, efficacy, and characterization of each compound — information that directly shapes whether these peptides can be legally compounded.

Briefing documents were published for:

• Introduction — the FDA's framing document for the meeting
• BPC-157 — ulcerative colitis
• KPV — wound healing and inflammatory conditions

• TB-500 — wound healing
• MOTS-c — obesity and osteoporosis
• Emideltide / DSIP — opioid withdrawal, insomnia, and narcolepsy
• Semax — cerebral ischemia, migraine, and trigeminal neuralgia
• Epitalon — insomnia

Key dates and how to weigh in

The public comment deadline for committee review is July 9, 2026, and the docket closes July 22, 2026. Comments can be submitted under Docket #FDA-2026-N-2979 at regulations.gov. The advisory committee meets on July 23–24, 2026, and its recommendations will help shape the compounding landscape for these peptides.

This article is for educational purposes and summarizes publicly reported regulatory developments as of July 1, 2026. It is not medical, legal, or regulatory advice. FDA advisory committee reviews are evaluations, not approvals, and outcomes may change. Newtropin is a wellness marketing firm and not a licensed pharmacy.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.